Wellnex Life Limited — Sale of Pain Away for up to A$21.3 million

Wellnex sells Pain Away for up to A$21.3m, aiming to clear all debt.

Risk flags

• ●The absence of audited financials for Pain Away and the lack of pro forma financials for Wellnex Life post-sale create significant uncertainty about the ongoing business’s profitability and sustainability. Investors cannot assess the impact of the divestment on future earnings or cash flow.
• ●The use of proceeds beyond debt repayment is not quantified or committed, with management only stating intentions for working capital, growth, or a possible return of capital. This lack of specificity leaves open the risk of suboptimal capital allocation or delayed shareholder returns.
• ●Completion is subject to customary closing conditions, including shareholder approval at a meeting scheduled for 8 September 2026. Any delay or failure to secure approval would postpone or jeopardize the transaction, directly affecting the anticipated debt repayment and capital return.
• ●The A$1.5 million earn-out is contingent on achieving threshold and target EBITDA over the 12 months post-completion. If operational performance falls short, the maximum consideration will not be realized, reducing the total inflow to Wellnex.
• ●A$1 million of the completion payment is held in escrow and released in tranches, subject to post-completion adjustments and claims. This delays access to a portion of the proceeds and exposes Wellnex to potential claims that could reduce the net cash received.

Bottom line

Wellnex Life’s sale of Pain Away is a material transaction that, if completed, will eliminate all company debt and provide surplus cash for potential reinvestment or capital return. The deal structure is transparent, but the lack of audited numbers and missing pro forma financials for the ongoing business means investors have no basis to assess the future earnings profile or value of Wellnex post-sale. Management’s statements about growth and capital returns are intentions, not commitments, and the actual allocation of surplus funds remains undecided. The transaction’s completion hinges on shareholder approval and standard closing conditions, with a near-term timeline but some execution risk. The most important takeaway is that while the divestment will clean up the balance sheet, the company’s future profitability and strategy remain unclear without further disclosure.

Announcement summary

(ASX:WNX) Wellnex Life Limited has entered into a formal binding agreement to sell its "Pain Away" business and assets to Mentholatum Australasia Pty Ltd for up to A$21.3 million in cash. The transaction includes an upfront purchase price of A$19.8 million payable at completion and an earn-out of up to A$1.5 million, subject to threshold and target normalised EBITDA performance during the 12 months post-completion. Pain Away contributed approximately $4.36 million in EBITDA and $13.38 million in revenue (both unaudited) to Wellnex Life during the financial year ended 30 June 2025, and had gross assets (unaudited) of $22.76 million as at 31 December 2025. Proceeds from the transaction will be used to retire all of the company's borrowings of approximately A$10.2 million, leaving Wellnex Life debt free at completion, with remaining funds to be used for working capital and potential return of capital to shareholders. Completion is subject to customary closing conditions, including shareholder approval, with a general meeting to seek approval scheduled for Tuesday 8 September 2026. The company projects that completion of the transaction is anticipated to occur shortly after shareholder approval is obtained, subject to satisfaction of the remaining conditions. The agreement includes an escrow arrangement for A$1 million of the completion payment and a 5-year restraint on competition in Australia and New Zealand.

Disagree with this article?